There is a great need to identify “safe” and effective therapies that may prevent and positively impact the progression of autoimmune disorders, like Type 1 diabetes (T1D). Omega-3 fatty acids and vitamin D are both safe therapies with known anti-inflammatory effects and immuno-modulating properties, respectively.  There have been several reports suggesting that there may be a potential beneficial effect from their use in diabetes.

Recently, investigators from several institutions in Italy in collaboration with Camillo Ricordi, M.D., Director of the Diabetes Research Institute at the University of Miami Miller School of Medicine, have reported on the case of an 8-year-old boy with new onset type 1 diabetes who was treated with vitamin D and high-dose Omega-3 fatty acids. Data on glucose control, exogenous insulin requirements, and insulin production from the native pancreas up to 16 months following diabetes onset were recently published in the European Review for Medical and Pharmacological Sciences.

Upon diagnosis, the patient was hospitalized and an islet autoantibody test confirmed he had type 1 diabetes. Additional test results showed a low vitamin D level, and the patient was started on vitamin D supplementation on a daily basis.

At five months post-diagnosis, the patient’s metabolic control substantially improved and his insulin requirements were reduced. Treatment with high-dose Omega-3 fatty acids was then introduced as an anti-inflammatory strategy aimed at potentially halting progression of autoimmunity and further loss of beta cell function. No adverse effects related to high-dose Omega-3 therapy were reported. The patient also maintained a gluten-free, high-fiber diet.

At 16 months post-diagnosis, the patient’s blood glucose control remained excellent with a reported total daily dose of approximately 1.5 units of insulin, or 0.05 units per kg per day, compared to 0.39 units per kg per day at diagnosis. Levels of C-peptide also increased, indicating insulin production from the native pancreas, from 0.5 mg/ml at diagnosis (fasting) to 0.6 mg/ml (fasting) and 1.6 mg/ml (post-meal). Based on this data, the researchers propose that therapy with both high-dose Omega-3 fatty acids and vitamin D may have contributed to the preservation of beta cell function and warrants further investigation.


Jose A Jimenez MD

OCC Internal Medicine

Intensive Care Medicine 

Share with

Back to Blog

OCC’s epidemiologist is closely monitoring the COVID-19 status and is actively issuing updates as they are available. The Centers for Disease Control and the World Health Organization are the most trusted sources online.  While the CDC has announced new mask protocols for vaccinated individuals, there will be no changes for our office protocols for patients, guests, and staff members as the announcement does not apply to hospitals or medical facilities. Masks are still a requirement for all patients, guests and staff at our facility.

As we reinitiate weight loss surgery, we are constantly adapting and installing new and updated safety measures.

Weight loss surgery is medically necessary.

Bariatric Surgery and the clash of two pandemics.   

Major metabolic and bariatric surgery Societies and colleges globally are now calling for the safe resumption of bariatric and metabolic surgery before the COVID-19 pandemic is declared over. 

The sooner bariatric surgery can be safely performed, the quicker obesity, type 2 diabetes, and other diseases can be reduced or resolved as they are not only chronic they are also progressive.  Obesity is also linked to more than 40 diseases including type 2 diabetes, hypertension, heart disease, stroke, sleep apnea, osteoarthritis, and at least 13 different types of cancer.

A recent statement from the ASMBS says “Before COVID-19 began, it was clear that patients with obesity were ‘safer through surgery.’ In the era of COVID-19, ‘safer through surgery’ for patients with obesity may prove to be even more important than before.” Obesity and Metabolic syndrome have been identified as an independent risk factor for adverse outcomes including death among COVID-19 patients.

See here for full COVID-19 update. 

Contact us media
Contact Us
Accessibility: If you are vision-impaired or have some other impairment covered by the Americans with Disabilities Act or a similar law, and you wish to discuss potential accommodations related to using this website, please contact our Accessibility Manager at 866-675-9912.
Contact Us